Besides, Piqray (alpelisib) from Novartis has been approved by FDA for the co-treatment with fulvestrant for PIK3CA-mutant HR-positive/HER2-negative late-stage/metastasis breast cancer, and this is the first PI3K inhibitor approved for breast cancer treatment [12]. This evidence concerns the gene PIK3CA and breast carcinoma.